See what the IHS Markit Score report has to say about Blueprint Medicines Corp. Wed, 15 Nov 2017 13:07:05 +0000 Short interest is low for BPMC with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding BPMC are favorable, with net inflows of $3.03 billion.
Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 15, 2017 Wed, 15 Nov 2017 12:51:12 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Blueprint Medicines Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
ETFs with exposure to Blueprint Medicines Corp. : November 6, 2017 Mon, 06 Nov 2017 16:13:01 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Blueprint Medicines Corp. Here are 5 ETFs with the largest exposure to BPMC-US. Comparing the performance and risk of Blueprint Medicines Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Blueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Fri, 03 Nov 2017 13:55:58 +0000 Categories: Yahoo FinanceGet free summary analysis Blueprint Medicines Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Blueprint Medicines Corp. – Newlink Genetics Corporation (NLNK-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 8.07 million, Net Earnings of USD -37.70 ... Read more
(Read more...)
Blueprint Medicines Announces Publication of BLU-285 Translational Data Wed, 01 Nov 2017 20:01:00 +0000 - Data published in Science Translational Medicine highlight the potential of BLU-285, a potent and highly selective KIT and PDGFRα inhibitor, to address unmet patient needs in GIST and SM - CAMBRIDGE, ...
Blueprint Medicines reports 3Q loss Tue, 31 Oct 2017 11:28:42 +0000 On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 96 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Blueprint Medicines Reports Third Quarter 2017 Financial Results Tue, 31 Oct 2017 11:00:00 +0000 - Presented clinical data from ongoing Phase 1 trial of BLU-554 in advanced hepatocellular carcinoma (HCC) at ESMO and ILCA 2017 Congress - - Updated BLU-285 data in advanced gastrointestinal stromal tumors ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.